Driven by robust imaging center demand, growth opportunities, and strong digital health investments, RadNet’s consensus analyst price target held steady at $77.43.
Analyst Commentary
- Robust core imaging center demand trends highlighted in recent management meetings.
- Multiple areas of opportunity for growth identified across the company's operations.
- Continued strong investment in Digital Health supporting the positive outlook.
- Ongoing brisk investment activity anticipated to fuel future expansion.
- Strategic positioning to augment organic growth with opportunistic M&A initiatives.
What's in the News
- RadNet raised full-year 2025 revenue guidance for its Imaging Center segment to $1,850–$1,900 million.
- The company secured reimbursement from major Southern California healthcare groups for its AI breast cancer detection program, increasing access for mammogram-eligible patients and launching proactive outreach to improve screening compliance.
- RadNet was added to multiple Russell value and small cap indices, including the Russell 2000, 2500, 3000, and Small Cap Comp Value benchmarks and indices.
Valuation Changes
Summary of Valuation Changes for RadNet
- The Consensus Analyst Price Target remained effectively unchanged, at $77.43.
- The Consensus Revenue Growth forecasts for RadNet remained effectively unchanged, at 7.6% per annum.
- The Net Profit Margin for RadNet remained effectively unchanged, at 8.37%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.